List of publications using Tiplaxtinin (Axon 1383) purchased from Axon Medchem

(Total 23 publication citations, updated AUGUST-2017)

Tseng, Y. J., Lee, C. H., Chen, W. Y., Yang, J. L., & Tzeng, H. T. (2021). Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade. Journal of Investigative Dermatology.

Bouarab, C., Roullot-Lacarrière, V., Vallée, M., Le Roux, A., Guette, C., Mennesson, M., ... & Revest, J. M. (2021). PAI-1 protein is a key molecular effector in the transition from normal to PTSD-like fear memory. Molecular Psychiatry, 1-14.

Tzeng, H. T., Yang, J. L., Tseng, Y. J., Lee, C. H., Chen, W. J., & Chyuan, I. T. (2021). Plasminogen Activator Inhibitor-1 Secretion by Autophagy Contributes to Melanoma Resistance to Chemotherapy through Tumor Microenvironment Modulation. Cancers, 13(6), 1253.

Park, L., Zhou, J., Koizumi, K., Wang, G., Anfray, A., Ahn, S. J., ... & Iadecola, C. (2020). tPA deficiency underlies neurovascular coupling dysfunction by amyloid-β. Journal of Neuroscience, 40(42), 8160-8173.

Griemert, E. V., Schwarzmaier, S. M., Hummel, R., Gölz, C., Yang, D., Neuhaus, W., ... & Thal, S. C. (2019). Plasminogen activator inhibitor‐1 augments damage by impairing fibrinolysis after traumatic brain injury. Annals of neurology, 85(5), 667-680.

Kubala, M. H., Punj, V., Placencio-Hickok, V. R., Fang, H., Fernandez, G. E., Sposto, R., & DeClerck, Y. A. (2018). Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer. Cell reports, 25(8), 2177-2191.

Gerenu, G., Martisova, E., Ferrero, H., Carracedo, M., Rantamäki, T., Ramirez, M. J., & Gil-Bea, F. J. (2017). Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1863(4), 991-1001.

Hosokawa, K., Ohnishi-Wada, T., Sameshima-Kaneko, H., Nagasato, T., Miura, N., Kikuchi, K., ... & Urano, T. (2016). Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in-vitro flow chamber model. Thrombosis research, 146, 69-75.
Lee, Y. C., Yu, C. C., Lan, C., Lee, C. H., Lee, H. T., Kuo, Y. L., ... & Chang, W. W. (2016). Plasminogen activator inhibitor‐1 as regulator of tumor‐initiating cell properties in head and neck cancers. Head & neck, 38(S1).
Pautus, S., Alami, M., Adam, F., Bernadat, G., Lawrence, D. A., De Carvalho, A., ... & Bonneau, N. (2016). Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1. Scientific reports, 6, 36462.
Thomas, A. X., Del Angel, Y. C., Gonzalez, M. I., Carrel, A. J., Carlsen, J., Lam, P. M., ... & Brooks-Kayal, A. R. (2016). Rapid increases in proBDNF after pilocarpine-induced status epilepticus in mice are associated with reduced proBDNF cleavage machinery. Eneuro, 3(1), ENEURO-0020.

Yang, A.T., Hu, D.D., Wang, P., Cong, M., Liu, T.H., Zhang, D., Sun, Y.M., Zhao, W.S., Jia, J.D. and You, H., 2016. TGF-1 Induces the Dual Regulation of Hepatic Progenitor Cells with Both Anti-and Proliver Fibrosis.
Daniel, A.E., Timmerman, I., Kovacevic, I., Hordijk, P.L., Adriaanse, L., Paatero, I., Belting, H.G. and van Buul, J.D., 2015. Plasminogen Activator Inhibitor-1 Controls Vascular Integrity by Regulating VE-Cadherin Trafficking. PloS one, 10(12).
*Tiplaxtinin and TM5276 were purchased from Axon Medchem.
Lee, Y.C., Yu, C.C., Lan, C., Lee, C.H., Lee, H.T., Kuo, Y.L., Wang, P.H. and Chang, W.W., 2015. Plasminogen activator inhibitor‐1 as regulator of tumor‐initiating cell properties in head and neck cancers. Head & neck.

New Protocol to Optimize iPS Cells for Genome Analysis of Fibrodysplasia Ossificans Progressiva.
Matsumoto, Y., Ikeya, M., Hino, K., Horigome, K., Fukuta, M., Watanabe, M., ... & Toguchida, J. (2015). 
Stem Cells. 2015 Jun;33(6):1730-42. doi: 10.1002/stem.1981. 

Plasminogen activator inhibitor‐1 regulates tumor initiating cell properties in head and neck cancers.
Lee, Y. C., Yu, C. C., Lan, C., Lee, C. H., Lee, H. T., Kuo, Y. L., ... & Chang, W. W. (2015).
Head Neck. 2015 May 13. doi: 10.1002/hed.24124. [Epub ahead of print]

Inhibition of PAI-1 via PAI-039 improves dermal wound closure in diabetes mellitus.
Rebalka, I. A., Raleigh, M. J., D’Souza, D. M., Coleman, S. K., Rebalka, A. N., & Hawke, T. J. (2015).
Diabetes. 2015 Mar 9. pii: db141174. [Epub ahead of print]

SIRT1-mediated epigenetic downregulation of plasminogen activator inhibitor-1 prevents vascular endothelial replicative senescence.
Wan YZ1, Gao P, Zhou S, Zhang ZQ, Hao DL, Lian LS, Li YJ, Chen HZ, Liu DP.
Aging Cell. 2014 Oct;13(5):890-9. doi: 10.1111/acel.12247. Epub 2014 Jul 18. 

PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation.
Giacoia EG1, Miyake M, Lawton A, Goodison S, Rosser CJ.
Mol Cancer Res. 2014 Mar;12(3):322-34. doi: 10.1158/1541-7786. 

Impaired Macrophage and Satellite Cell Infiltration Occurs in a Muscle-Specific Fashion Following Injury in Diabetic Skeletal Muscle. 
MP Krause, D Al-Sajee, DM D’Souza, IA Rebalka, J Moradi, MC Riddell, & TJ Hawke. 
PLoS One. 2013 Aug 12;8(8):e70971. doi: 10.1371/journal.pone.0070971. 

An in vitro model for the pro-fibrotic effects of retinoids: Mechanisms of action. 
AC Rankin, BM Hendry, JP Corcoran, Q Xu. 
Br J Pharmacol. 2013 Nov;170(6):1177-89. doi: 10.1111/bph.12348. 

Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.
Gomes-Giacoia E1, Miyake M, Goodison S, Rosser CJ.
Mol Cancer Ther. 2013 Dec;12(12):2697-708. doi: 10.1158/1535-7163.MCT-13-0500. Epub 2013 Sep 26. 

Valproic acid induces astrocyte-dependent neurite outgrowth from cultured rat primary cortical neuron via modulation of tPA/PAI-1 activity. 
KS Cho, KJ Kwon, CS Choi, SJ Jeon, KC Kim, JH Park, HM Ko, SH Lee, JH Cheong, JH Ryu, SH Han, CY Shin.
Glia. 2013 May;61(5):694-709. doi: 10.1002/glia.22463. Epub 2013 Feb 4.

TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells. 
H Yasui, Y Suzuki, H Sano, T Suda, K Chida, T Dan, T Miyata, T Urano. 
Thromb Res. 2013 Jul;132(1):100-5. doi: 10.1016/j.thromres.2013.04.003. Epub 2013 Apr 20.

2012 and earlier
Boolean approach to signalling pathway modelling in HGF-induced keratinocyte migration.
A Singh, JM Nascimento, S Kowar, H Busch, M Boerries
Bioinformatics. 2012 Sep 15;28(18):i495-i501. doi: 10.1093/bioinformatics/bts410.

Protumorigenic Activity of Plasminogen Activator Inhibitor-1 Through an Antiapoptotic Function.
H Fang, VR Placencio, YA DeClerck.
J Natl Cancer Inst. 2012 Oct 3;104(19):1470-84. doi: 10.1093/jnci/djs377. Epub 2012 Sep 13.

Neutrophil–cytokine interactions in a rat model of sulindac-induced idiosyncratic liver injury.
W Zou, RA Roth, HS Younis, E Malle, PE Ganey.
Toxicology. 2011 Dec 18;290(2-3):278-85. doi: 10.1016/j.tox.2011.10.005. Epub 2011 Oct 14.

Inhibition of plasminogen activator inhibitor-1 restores skeletal muscle regeneration in untreated type 1 diabetic mice.
MP Krause, J Moradi, AA Nissar, MC Riddell, TJ Hawke.
Diabetes. 2011 Jul;60(7):1964-72. doi: 10.2337/db11-0007. Epub 2011 May 18.

Theaflavin digallate inactivates plasminogen activator inhibitor: Could tea help in Alzheimer's disease and obesity?
E Skrzypczak-Jankun, & J Jankun. 
Int J Mol Med. 2010 Jul;26(1):45-50.

(This is an incomplete list, updated in AUGUST-2017) 


Please wait...